Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsUtilization of an Eilat Virus-Based Chimera for Serological Detection of Chikungunya InfectionEarly Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane FusionExposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacyChikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoesMultiple immune factors are involved in controlling acute and chronic chikungunya virus infectionSeroprevalence of Anti-Chikungunya Virus Antibodies in Children and Adults in Managua, Nicaragua, After the First Chikungunya Epidemic, 2014-2015A CRISPR screen defines a signal peptide processing pathway required by flavivirusesChikungunya vaccines in developmentA potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesisNonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model)A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from diseaseTherapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritisChikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.Animal Models of Chikungunya Virus Infection and Disease.Sindbis virus as a human pathogen-epidemiology, clinical picture and pathogenesis.Discovery of an antibody for pan-ebolavirus therapyDysregulated TGF-β Production Underlies the Age-Related Vulnerability to Chikungunya Virus.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Human-like antibodies neutralizing Western equine encephalitis virus.Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.Chikungunya virus infection in Cynomolgus macaques following Intradermal and aerosol exposure.Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challengeChronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis.Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPsIsolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.Chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritisThe neutralizing role of IgM during early Chikungunya virus infectionCryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activityBroadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.Plasmodium falciparum Histidine-Rich Protein II Compromises Brain Endothelial Barriers and May Promote Cerebral Malaria Pathogenesis.Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses.Alphavirus mutator variants present host-specific defects and attenuation in mammalian and insect modelsA novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
P2860
Q24289014-31878926-FC65-4C8E-9C6D-11F43D3F6458Q24701740-3C952EDE-A7BA-426C-B19C-3184A2A06C3BQ24701760-92A8BE3E-CBFE-4E4F-A9F6-5D119B964641Q24701766-E3A84718-1EBA-4110-8BD5-9B9B6CAFAD3EQ24701786-D88D64BE-AF8D-443A-802D-BA0FCA2D8A5FQ24701792-897E062F-DCDE-44A2-8552-32BE3F139C4BQ24705133-FB506FEF-C3C4-4689-BDB9-8851FB18E050Q24705237-9CB30C2F-6750-408B-9F2F-2BDEA4740A68Q26700081-7CCC0D1F-1CCD-4883-BBF3-4E912A65C621Q26700129-37163922-673A-4A4A-97B5-8A0E6697C5D7Q26782722-E230E8AC-9136-4938-9778-6BA829B068FEQ28533408-073556B4-4D96-4A7C-BA00-7207D65438A6Q28656412-C31B18DF-F3E8-467D-B7C9-E8BE36DC2CD0Q30235512-DF77B573-30D1-425F-8C26-02E91A4D2E50Q30240216-86C0443E-ABE1-41EE-84C4-661571FEFEC1Q30251764-EC1BA2E2-1775-42C0-9DCA-794A86E00C81Q30385927-0FE6D896-FEB1-41A6-97FD-63D441CF87F8Q30394063-1705BE9E-FC07-41BB-9661-656F74A962D5Q33425879-DE3B2CEE-3210-4722-B087-D2AE91BD44D5Q33573599-8CCBB9F6-D524-467B-9DCE-2188A4CEE2C4Q33853893-C3C98136-6497-43B4-B390-171506BEB8A6Q33921915-16BBDF13-ACEC-4F6C-AC51-D62C228683E3Q34361120-F24A7C7A-BA66-40A8-840C-518C8D5000DEQ34378105-9DE750EC-9832-454C-9965-1137C3499811Q34810471-68F6C621-964E-48F9-9BF3-704B19142131Q35152251-F6BDB18A-9808-459B-B097-F11F5FCD1BA9Q35155037-71CF469D-1F2B-4613-9AF9-44168F136F46Q35675647-D244FA78-D647-4198-9B89-40D7BAD92170Q35850197-6185E7F5-AE71-4DF8-B2E7-1D2042C0580DQ36114846-5BC456E1-38C9-414A-BA7F-3DF8860B5D5FQ36275851-E48A94AF-757E-45CD-A6B6-23395E487D8FQ36300209-A2A175D1-E67E-4A42-8882-59C1CF3306B3Q36318652-48D801D9-16CC-4EF1-8FDD-4D2FBB0AE2E5Q36483436-71E0B9E9-E6B8-46E0-BAF0-4B6163588D40Q37123466-BA44ACD1-6821-44B7-A6BF-DF37F467E7A8Q37214518-10415D0C-875F-4929-8BCF-F4265966386DQ37252899-7400652F-8C50-4997-808C-6A2692616ACFQ37488102-BAE7BFF3-9852-46A7-8009-D4417F4354D0Q37643733-27A80993-A3F3-4CE8-8A24-C44273A77342Q37711813-38FF4A6D-1A41-4913-8E70-70DB94FED30A
P2860
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Development of a highly protec ...... rapy against Chikungunya virus
@ast
Development of a highly protec ...... rapy against Chikungunya virus
@en
Development of a highly protec ...... rapy against Chikungunya virus
@nl
type
label
Development of a highly protec ...... rapy against Chikungunya virus
@ast
Development of a highly protec ...... rapy against Chikungunya virus
@en
Development of a highly protec ...... rapy against Chikungunya virus
@nl
prefLabel
Development of a highly protec ...... rapy against Chikungunya virus
@ast
Development of a highly protec ...... rapy against Chikungunya virus
@en
Development of a highly protec ...... rapy against Chikungunya virus
@nl
P2093
P2860
P50
P3181
P1433
P1476
Development of a highly protec ...... rapy against Chikungunya virus
@en
P2093
Daved H Fremont
James D Brien
Jolanda M Smit
Mareike K S Richter
Melissa A Edeling
Pankaj Pal
Sergey Gorlatov
Syd Johnson
Wataru Akahata
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1003312
P407
P5008
P577
2013-01-01T00:00:00Z